New Ventures

How we work

We employ a unique in-house model to refine and de-risk commercially viable new venture opportunities at UHN. Our team of seasoned industry business development experts, IP specialists and legal counsel, in concert with our Entrepreneurs-in-Residence, work on nurturing newly-founded companies – maximizing patient impact around the world.

Our new ventures contain robust IP portfolios, most-often equipped with long-term protection.

MORE on our unique approach

Many of our more mature companies are open to later-stage investments.

view Companies


Treating atrial fibrillation with conductive biomaterials

Medly Therapeutics

Digital health platform transforming care for heart failure /chronic conditions

Curait Medical

AI-driven quality assurance platform for radiation oncology


Biologic in development for CNS disorders with applications in ophthalmology


Nanomedicine therapeutic opportunity with new generation of multi-capacity photosensitizers (porphysomes)


Improving cardiac arrest survival rates after ventricular fibrillation (VF)


Small Molecule Therapeutics for Rare and Neurodegenerative Diseases

DNT Therapeutics

Novel form of cell therapy platform


Harnessing the power of cytokines for the treatment of cancer.